Interferon-alpha2b with protease inhibitor-based antiretroviral therapy in patients with AIDS-associated Kaposi sarcoma

Article Abstract:

The safety and maximum tolerated dose of interferon (IFN)alpha2b in combination with protease inhibitor-based highly active antiretroviral therapy (HAART) in a phase 1 study in 14 patients with AIDS-association Kaposi sarcoma (KS) is evaluated. A safe dose of IFN that can be used with HAART and, potentially, with other inhibitors of KS in future clinical trails is established.

United States, General services, Biological Product (except Diagnostic) Manufacturing, Biological products exc. diagnostic, Interferon, Safety and security measures, Drug therapy, Dosage and administration, Antiviral agents, Kaposi's sarcoma, Antiretroviral agents

---

Impact of syphilis infection on HIV viral load and CD4 cell counts in HIV-infected patients

Article Abstract:

A study was conducted to assess the effect of early syphilis on HIV viral load (VL) and CD4 cell count in patient with HIV and to analyze factors associated with changes in HIV VL and CD4 cell count. The result data confirm that syphilis infection in HIV-infected patients was associated with a significant decrease in CD4 cell count and an increase in plasma HIV VL.

Health aspects, Risk factors, HIV patients, Syphilis, Viremia, CD4 lymphocytes, Viral load, Clinical report

---

Similar abstracts:

• Abstracts: Long-term vasodilator therapy in patients with severe aortic regurgitation. Long-term follow-up of idiopathic chronic pericardial effusion
• Abstracts: Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: The Swiss HIV cohort study
• Abstracts: Gender differences in AIDS-associated Kaposi Sarcoma in Harare, Zimbabwe. Improving HIV surveillance in Victoria: The role of "detuned" enzyme immunoassay

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.